Ovid Therapeutics INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Ovid Therapeutics Inc. has filed its definitive proxy statement for the 2026 Annual Meeting of Stockholders to be held virtually on June 10, 2026.
NASDAQ
Ovid Therapeutics calls a Special Meeting to approve a significant increase in authorized common stock and the issuance of shares related to a recent $80.8 million PIPE financing.
NASDAQ
Ovid Therapeutics Inc. has filed a definitive proxy statement with the SEC regarding its upcoming shareholder meeting.
NASDAQ
DEF: Ovid Therapeutics Seeks Stockholder Approval for Reverse Stock Split to Maintain Nasdaq Listing
Ovid Therapeutics is asking stockholders to approve a reverse stock split to maintain its Nasdaq listing and improve stock marketability.
NASDAQ
Ovid Therapeutics Inc. has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.
NASDAQ
Ovid Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 6, 2024, to vote on director elections, executive compensation, and auditor ratification.